Precigen, Inc. discovers and develops the next generation of cell and gene therapies in the United States. The company is headquartered in Germantown, Maryland.
| Revenue (TTM) | $156.94M |
| Gross Profit (TTM) | $116.93M |
| EBITDA | $38.08M |
| Operating Margin | 52.10% |
| Return on Equity | 38.80% |
| Return on Assets | 11.00% |
| Revenue/Share (TTM) | $0.44 |
| Book Value | $0.23 |
| Price-to-Book | 18.06 |
| Price-to-Sales (TTM) | 10.21 |
| EV/Revenue | 9.98 |
| EV/EBITDA | 38.30 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 2438.00% |
| Shares Outstanding | $358.55M |
| Float | $194.88M |
| % Insiders | 12.62% |
| % Institutions | 72.51% |
Volatility is currently expanding
Precigen NASDAQ: PGEN reported $72.9 million in third-quarter 2026 sales of PAPZIMEOS, its treatment for adults with recurrent respiratory papillomatosis, as the company posted a second consecutive profitable quarter and generated positive cash flow ahead of its prior expectations.
PAPZIMEOS ® net revenue rose 37% quarter-over-quarter to $72.9 million in the third quarter of 2026 bringing launch-to-date net product revenue to $151 million, underscoring sustained commercial momentum and expanding US adoption Achieved positive cash flow in the third quarter of 2026, a full quarter ahead of guidance, driven by robust PAPZIMEOS uptake Net income for the third quarter of $35.8 million Cash, cash equivalents, and investments totaled $51.0 million as of September 30, 2026 Received FDA Platform Technology Designation for the AdenoVerse ® platform, creating opportunities to expedite development of current and future therapies New long-term follow-up data presented at AAO-HNSF 2026 demonstrated ongoing durable complete responses after PAPZIMEOS treatment for up to five years Conference call scheduled for 4:30 PM ET today GERMANTOWN, Md., Nov. 4, 2026 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a commercial-stage biopharmaceutical company specializing in the advancement of innovative precision medicines to improve the lives of patients, today announced third quarter 2026 financial results and business updates.
PGEN's Q3 results hinge on Papzimeos sales momentum and pipeline updates as competitive threat grows from a newly approved RRP therapy.
GERMANTOWN, Md., Oct. 28, 2026 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a commercial-stage biopharmaceutical company specializing in the advancement of innovative precision medicines to improve the lives of patients, today announced the Company will release third quarter 2026 financial results and provide business updates on Wednesday, November 4, 2026.
Precigen is building momentum with Papzimeos sales growth, a European regulatory review and progress across its AdenoVerse pipeline.
ABT, CORT, PGEN and BHC offer low-beta healthcare exposure as rate-hike fears and market volatility persist.
Precigen (PGEN) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Precigen's Papzimeos and Ironwood's Linzess are driving growth, but competition, pipeline progress and single-product reliance shape each biotech's outlook.
Precigen just received an FDA "platform technology designation" for AdenoVerse, something that validates its versatility and accelerates its pipeline. PAPZIMEOS, the first FDA-approved product from AdenoVerse, is now the first-line standard of care for RRP with rapid payer coverage and strong uptake. PGEN targets a $2B peak global sales opportunity, with EMA approval for PAPZIMEOS potentially doubling the addressable market by year-end or early 2027.
Precigen's Papzimeos is gaining commercial momentum, while its pipeline potential through the AdenoVerse platform could create new growth opportunities.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on PGEN and any ticker you trade — then tracks every position and per-strategy win rate.
